Truist Financial analyst Joon Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Verona Pharma has a 12-month low of $11.39 and a 12-month high of $55.91. The company has a market cap of $4.44 billion, a P/E ratio of -28.47 and a beta of 0.40.

On Tuesday, H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares. The ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the shares following the “massive” Q4 revenue beat.

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure ...